MPM BioImpact LLC Discloses 8.8% Stake in DBV Technologies S.A.

MPM BioImpact LLC has filed a Schedule 13G/A (Amendment No. 1) regarding its holdings in DBV Technologies S.A. (DBVT). As of the event date on March 31, 2026, the reporting person disclosed beneficial ownership of 26,066,806 ordinary shares, representing an 8.8% stake in the company. This position consists of one direct ordinary share and 26,066,805 ordinary shares represented by American Depositary Shares (ADSs), with each ADS representing five ordinary shares. MPM BioImpact LLC reported sole voting and dispositive power over the entire share amount. The filing indicates a significant increase from the previously reported 0.0% ownership, establishing a substantial passive investment position in the clinical-stage biopharmaceutical company. The reporting person is an investment adviser based in Boston, MA, and certified that the shares were acquired in the ordinary course of business without the intent to influence or change the control of the issuer. The calculation is based on 296,042,447 outstanding ordinary shares as of April 30, 2026.